DOCSLIB.ORG

Screening for Lipid Disorder: Systematic Evidence Review

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Screening for Lipid Disorder: Systematic Evidence Review On December 6, 1999, under Public Law 106-129, the Agency for Health Care Policy Research (AHCPR) was reauthorized and renamed the Agency for Healthcare Research and Quality(AHRQ). The law authorizes AHRQ to continue its research on the cost, quality, and outcomes of health care, and expands its role to improve patient safety and address medical errors. This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied. Systematic Evidence Review Number 4 Screening for Lipid Disorders Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 2101 East Jefferson Street Rockville, MD 20852 http://www.ahrq.gov Contract No. 290-97-0011 Task Order No. 3 Technical Support of the U.S. Preventive Services Task Force Prepared by: Research Triangle Institute University of North Carolina Evidence-based Practice Center Michael P. Pignone, M.D., M.P.H. Christopher J. Phillips, M.D., M.P.H. Carole M. Lannon, M.D., M.P.H. Cynthia D. Mulrow, M.D., M.Sc. Steven M. Teutsch, M.D., M.P.H. Kathleen N. Lohr, Ph.D. B. Lynn Whitener, Dr.P.H., M.S.L.S. AHRQ Publication No. 01-S004 April 2001 The authors of this report are responsible for its content. Statements in the report should not be construed as endorsement by the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services of a particular drug, device, test, treatment, or other clinical service. Preface The Agency for Healthcare Research and Quality (AHRQ) sponsors the development of Systematic Evidence Reviews (SERs) through its Evidence-based Practice Program. With ∗ guidance from the third U.S. Preventive Services Task Force (USPSTF) and input from Federal partners and primary care specialty societies, two Evidence-based Practice Centers— one at the Oregon Health Sciences University and the other at Research Triangle Institute- University of North Carolina—systematically review the evidence of the effectiveness of a wide range of clinical preventive services, including screening, counseling, immunizations, and chemoprevention, in the primary care setting. The SERs—comprehensive reviews of the scientific evidence on the effectiveness of particular clinical preventive services--serve as the foundation for the recommendations of the third USPSTF, which provide age- and risk- factor-specific recommendations for the delivery of these services in the primary care setting. Details of the process of identifying and evaluating relevant scientific evidence are described in the “Methods” section of each SER. The SERs document the evidence regarding the benefits, limitations, and cost-effectiveness of a broad range of clinical preventive services and will help to further awareness, delivery, and coverage of preventive care as an integral part of quality primary health care. AHRQ also disseminates the SERs on the AHRQ Web site (http://www.ahrq.gov/uspstfix.htm) and disseminates summaries of the evidence (summaries of the SERs) and recommendations of the third USPSTF in print and on the Web. These are available through the AHRQ Web site (http://www.ahrgq.gov/uspstfix.htm), through the National Guideline Clearinghouse (http://www.ncg.gov), and in print through the AHRQ Publications Clearinghouse (1-800-358- 9295). We welcome written comments on this SER. Comments may be sent to: Director, Center for Practice and Technology Assessment, Agency for Healthcare Research and Quality, 6010 Executive Blvd., Suite 300, Rockville, MD 20852. John M. Eisenberg, M.D. Douglas B. Kamerow, M.D. Director Director, Center for Practice and Agency for Healthcare Research and Quality Technology Assessment Agency for Healthcare Research and Quality ∗ The USPSTF is an independent panel of experts in primary care and prevention first convened by the U.S. Public Health Service in 1984. The USPSTF systematically reviews the evidence on the effectiveness of providing clinical preventive services--including screening, counseling, immunization, and chemoprevention--in the primary care setting. AHRQ convened the third USPSTF in November 1998 to update existing Task Force recommendations and to address new topics. Structured Abstract Context Lipid disorders are an important risk factor for coronary heart disease (CHD). Screening and treatment of lipid disorders in persons at high risk for future CHD events have gained wide acceptance, especially for patients with known CHD, but the proper role in persons with low to medium risk is controversial. Objective To examine the evidence about the benefits and harms of screening and treatment of lipid disorders in adults, adolescents, and children for the US Preventive Services Task Force. Data Sources We identified English-language articles on drug therapy, diet and exercise therapy, and screening for lipid disorders from comprehensive searches of the MEDLINE database from January1994 through July 1999. We used published systematic reviews, hand searching of relevant articles, the second Guide to Clinical Preventive Services, and extensive peer review to identify important older articles and ensure completeness. Study Selection We included all randomized trials of at least 1 year’s duration that examined drug or diet therapy among patients without previously known CHD and that measured clinical endpoints, including total mortality, CHD mortality, or nonfatal myocardial infarctions. We also included randomized trials of diet or exercise therapy that measured change only in total cholesterol. To examine the question of screening, we included articles that addressed the epidemiology and natural history of lipid levels and lipid disorders or that measured the accuracy, reliability, acceptability, and feasibility of screening. We also included any articles that examined adverse effects and harms of screening or therapy for lipid disorders. Data Extraction We extracted the following data from the included articles: demographic details about subjects; inclusion and exclusion criteria; and study design, duration, interventions, and outcome measures. We evaluated the internal and external validity of each article and judged the overall quality of evidence by examining aggregate internal and external validity and coherence of the results. Data Synthesis There is strong, direct evidence that drug therapy reduces CHD events and CHD mortality in middle-aged men (35 to 70 years of age) with abnormal lipids and a potential risk of CHD events greater than 1%per year. Drug therapy may also reduce total mortality in patients at higher risk (greater than 1.5% per year). Less direct evidence suggests that drug therapy is also effective in other adults, including older men (over the age of 70 years) and middle-aged and older women (ages 45 years and older) with similar levels of risk. Trials of diet therapy for primary prevention have led to long-term reductions in cholesterol of 3% to 6%but have not demonstrated a reduction in CHD events overall. Exercise programs that maintain or reduce body weight can produce short-term reductions in total cholesterol of 3% to 6% but longer-term results in unselected populations have found small reductions or no effect. Screening middle-aged and older men and women for lipid disorders can accurately identify persons at increased CHD risk who may benefit from therapy. The evidence is insufficient about benefits and harms of screening and treating persons at low absolute risk, including most men under 35 years of age, women under 45 years, and children and adolescents. To identify accurately persons with abnormal lipids, at least 2 measurements of total cholesterol and high-density lipoprotein cholesterol (HDL) are required. The role of measuring triglycerides and the optimal screening interval are unclear from the available evidence. Conclusion Strong evidence shows the effectiveness of therapy for lipid disorders in middle-aged men; indirect evidence shows effectiveness in older men and women of sufficient risk. Screening for lipid disorders with total cholesterol and HDL and performing a global assessment of CHD risk can accurately identify those at sufficient risk who can benefit from treatment. Key Word: Cardiovascular diseases – cholesterol – hyperlipidemia - preventive health services - evidence-based medicine – MEDLINE – methods – lipids - mass screening – mortality - drug therapy This document is in the public domain and may be used and reprinted without permission except those copyrighted materials noted for which further reproduction is prohibited without the specific permission of copyright holders. Suggested Citation: Pignone MP, Phillips CJ, Lannon CM, et al. Screening for Lipid Disorders, Systematic Evidence Review No.4 (Prepared by the Research Triangle Institute—University or North Caroline Evidence-based Practice Center, under contract No. 290-98-0011). AHRQ Publication No. AHRQ 01-S004. Rockville, MD: Agency for Healthcare Research and Quality. April 2001. Acknowledgments This study was supported by Contract 290-97-0011 from the Agency for Healthcare Research and Quality (Task No. 3 to support the US Preventive Services Task Force). We acknowledge the ongoing guidance and assistance of David Atkins, M.D., M.P.H., Director of the Clinical Preventive Services program at AHRQ, Dana Best, M.D., the Task Order Officer for this project, and Jacqueline Besteman, J.D., M.A., the Program Officer in the Center for Practice and Technology Assessment for the entire AHRQ Evidence-based Practice Center program.. We also acknowledge the assistance of Eve Shapiro, Managing Editor, under contract to the AHRQ Office of Health Care Information. The investigators deeply appreciate the considerable support and contributions of faculty and staff from the University of North Carolina at Chapel HillTimothy S. Carey, M.D., M.P.H.; Co-Director of the RTI-UNC EPC; Russell P. Harris, M.D., M.P.H., Co- Director of the RTI-UNC EPC’s Clinical Prevention Center; Anne Jackman, M.S.W.; Barbara E. Starrett, M.H.A.; Alyssa Wood, M.F.A., and Carol Krasnov.
Load more

Recommended publications
  • An Educational Booklet for Patients with Familial Hypercholesterolemia
    Illustrations > Jean Lambert Illustrations graphic design > www.mine-de-rien.net graphic Chol/29/P030/01-01/10 NLA An educational booklet for patients with familial hypercholesterolemia This brochure was provided by Genzyme Corporation for use by the Foundation of the National Lipid Association. DR. LEIV OSE www.learnyourlipids.com CONTENTS PART 1 What will you learn from this booklet? 02 FAMILIAL HYPERCHOLESTEROLEMIA PART 1: FAMILIAL HYPERCHOLESTEROLEMIA 03 1 - What is Familial Hypercholesterolemia? 03 WHAT WILL YOU 2 - What is LDL-Cholesterol? 04 3 - What are the causes of FH? 05 LEARN FROM THIS GREAT GRANDMOTHER GREAT GRANDFATHER 4 - When should FH be suspected? 07 FH NON FH BOOKLET? 5 - How is FH diagnosed? 09 6 - How early can FH be diagnosed? 09 Woman You will learn about Familial PART 2: TREATMENT 10 GRANDMOTHER GRANDFATHER Hypercholesterolemia, NON FH FH Woman with FH 1 - How can LDL-Cholesterol be reduced? 10 its cause, and the potential 2 - Step 1: Dietary management of FH 11 Man consequences of this a) How does diet affect LDL-Cholesterol? 11 disease. You will learn b) What sort of diet? 11 Man with FH about high cholesterol 3 - Step 2: Using medication 12 AUNT MOTHER FATHER UNCLE and what this might mean a) How does medication affect LDL-Cholesterol? 12 NON FH FH NON FH FH for your heart and blood b) Which drug treatments reduce LDL-Cholesterol and how? 13 FIGURE 1: 4 - Why is lifelong treatment important? vessels. Most importantly 15 FH is an inherited disease, you will learn how to find PART 3: CARDIOVASCULAR DISEASE AND LIPOPROTEINS 16 which can usually be traced out whether someone in 1 - What is cardiovascular disease? 16 DAUGTER SON over several generations.
    [Show full text]
  • Core Laboratory
    Performance of the vast majority of Hematology, Coagulation, Urinalysis, Clinical Chemistry and Toxicology testing procedures is conducted in the CORE LABORATORY - an advanced, highly automated area where whole blood, serum, plasma, urine and other biological fluid specimens are tested for a comprehensive menu of state-of-the-art laboratory procedures. Significant testing procedures for Clinical Chemistry and Toxicology includes panels currently approved by the Centers for Medicare and Medicaid Services: Basic Metabolic Panel; Comprehensive Metabolic Panel; Liver Function Panel; Renal Function Panel; and Electrolyte Panel. Other key tests include the Lipid Profile (Cholesterol, Triglyceride, HDL- Cholesterol and LDL-Cholesterol), major markers of cardiovascular disease and risk [such as Troponin I, Myoglobin and Beta-type natriuretic peptide (commonly referred to as BNAT or BNP)], critical care analytes, beta-HCG, and significant therapeutic drug levels. Urinary toxicology screens for major drugs of abuse (and/or key metabolites) are also performed. The cornerstones of Hematology testing are analyses of the complete blood count (CBC) and the differential (DIFF). These include evaluation of: (1) white blood cell count and differential with percentage and absolute value given for the leukocyte components; (2) circulating erythrocytes by means of hemoglobin, hematocrit, red blood cell count, and red blood cell indices; and (3) measurement of platelet concentration by count and/or estimation. Morphological variations and changes of cellular constituents are reported. Alteration of any aspect of the hemostatic mechanism may cause abnormal bleeding in a wide variety of familial and acquired disorders. These defects may be differentiated by a profile of significant Coagulation laboratory tests that includes PT, PTT, Fibrinogen, FDP, and D-Dimer for monitoring anticoagulant therapy.
    [Show full text]
  • Genetic Testing for Familial Hypercholesterolemia AHS – M2137
    Corporate Medical Policy Genetic Testing for Familial Hypercholesterolemia AHS – M2137 File Name: genetic_testing_for_familial_hypercholesterolemia Origination: 01/01/2019 Last CAP Review: 07/2021 Next CAP Review: 07/2022 Last Review: 07/2021 Description of Procedure or Service Definitions Familial hypercholesterolemia (FH) is a genetic condition that results in premature atherosclerotic cardiovascular disease due to lifelong exposure to elevated low-density lipoprotein cholesterol (LDL-C) levels (Sturm et al., 2018). FH encompasses multiple clinical phenotypes associated with distinct molecular etiologies. The most common is an autosomal dominant disorder caused by mutations in one of three genes, low-density lipoprotein receptor (LDLR), apolipoprotein B-100 (APOB), and proprotein convertase subtilisin-like kexin type 9 (PCSK9) (Ahmad et al., 2016; Goldberg et al., 2011). Rare autosomal recessive disease results from mutation in low-density lipoprotein receptor adaptor protein (LDLRAP) (Garcia et al., 2001). Related Policies Cardiovascular Disease Risk Assessment AHS – G2050 ***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician. Policy BCBSNC will provide coverage for genetic testing for familial hypercholesterolemia when it is determined the medical criteria or reimbursement guidelines below are met. Benefits Application This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy. When Genetic Testing for Familial Hypercholesterolemia is covered 1. Genetic testing to establish a molecular diagnosis of Familial Hypercholesterolemia is considered medically necessary when BOTH of the following criteria are met: A.
    [Show full text]
  • Inflammatory Mechanisms Affecting the Lipid Profile in Patients with Systemic Lupus Erythematosus CECILIA P
    Inflammatory Mechanisms Affecting the Lipid Profile in Patients with Systemic Lupus Erythematosus CECILIA P. CHUNG, ANNETTE OESER, JOSEPH SOLUS, INGRID AVALOS, TEBEB GEBRETSADIK, AYUMI SHINTANI, MacRAE F. LINTON, SERGIO FAZIO, and C. MICHAEL STEIN ABSTRACT. Objective. Increased low density lipoprotein (LDL) cholesterol and triglycerides, and decreased high density lipoprotein (HDL) cholesterol concentrations are associated with adverse cardiovascular risk in the general population. Patients with systemic lupus erythematosus (SLE) have an altered lipid profile characterized by increased triglycerides and decreased HDL cholesterol concentrations. We examined the relationships between lipid concentrations, cytokines, and inflammatory markers in patients with SLE. Methods. Fasting lipid concentrations, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were measured in 110 patients with SLE. Disease activity was quantified by the SLE Disease Activity Index (SLEDAI), and disease damage by the Systemic Lupus International Collaborating Clinics (SLICC) score. Concentrations of circulating tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6), and insulin were measured and insulin sensitivity calculated. Results. Lower concentrations of HDL cholesterol were independently associated with higher ESR (p < 0.001), IL-6 (p = 0.02), SLEDAI (p = 0.04), and TNF-α (p = 0.04) after adjustment for age, sex, race, body mass index, insulin sensitivity, and current use of corticosteroids or hydroxychloroquine. Triglyceride concentrations were
    [Show full text]
  • Lipid Profile and Its Relationship with Blood
    Onkar Singh et al. Lipid profile and blood glucose levels in MetS National Journal of Physiology, DOI: 10.5455/njppp.2015.5.051120141 NJPPP Pharmacy & Pharmacology http://www.njppp.com/ RESEARCH ARTICLE Correspondence LIPID PROFILE AND ITS RELATIONSHIP Onkar Singh ([email protected]) WITH BLOOD GLUCOSE LEVELS IN Received 27.08.2014 METABOLIC SYNDROME Accepted 09.09.2014 1 1 2 Onkar Singh , Mrityunjay Gupta , Vijay Khajuria Key Words Metabolic Syndrome; 1 Department of Physiology, Government Medical College, Jammu, India Dyslipidemia; Lipid Pattern; 2 Department of Pharmacology, Government Medical College, Jammu, India Type 2 Diabetes Mellitus Background: Metabolic syndrome (MetS) and its associated factors such as dyslipidemia and hyperglycemia are associated with increased risk of cardiovascular disease (CVD). Aims and Objective: To assess lipid profile and its relation with blood glucose levels in patients with MetS. Materials and Methods: This cross-sectional study included 72 male patients with MetS. Anthropometry, lipid profile, blood glucose, and presence of MetS (JIS criteria) were determined. Results: High triglyceride (TG) level (>200 mg/dL, 44.4%) was the most common dyslipidemia followed by low levels of high-density lipoprotein cholesterol (<40 mg/dL, 19.4%). High total cholesterol levels (>240 mg/dL, 13.8%) and high low- density lipoprotein cholesterol levels (>160 mg/dL, 9.7%) were observed. On comparison, no significant differences in lipid levels of MetS patients with normal fasting glucose, impaired fasting glucose, and type 2 diabetes mellitus were observed. Conclusions: Dyslipidemia was frequent in patients with MetS. High TG was the most common lipid abnormality, and a large number of patients had more than one abnormal lipid parameter.
    [Show full text]
  • Community Lab Costs
    Sickle Cell This tests for the genetic trait which may lead to sickle cell anemia. Osteoporosis Screening This uses ultrasound to screen people for low bone density or osteoporosis and is completed by painlessly scanning the heel. Because osteoporosis rarely causes signs or symptoms until it’s advanced, the National Osteoporosis Foundation recommends a bone density test if you are: • A woman older than age 65 or a man older than age 70 • A postmenopausal woman with at least one risk factor for osteoporosis Community Lab Costs • A man between age 50 and 70 who has at least one osteoporosis (greatly reduced rates) risk factor • Older than age 50 with a history of a broken bone • Taking medications, such as prednisone, aromatase inhibitors or Wellness Panel........................................................................ $20 Fasting anti-seizure drugs, that are associated with osteoporosis Includes screening for glucose, electrolytes, kidney, liver and • A postmenopausal woman who has recently stopped taking thyroid, plus complete blood count and lipid profile hormone therapy • A woman who experienced early menopause Diabetic Screening (A1c)...................................................... $5 The results of this test will indicate if you have or at risk for osteoporosis. Sickle Cell................................................................................ $6 If so, your doctor can offer treatment. PSA (Prostate Screening)...................................................... $8 Breathing Test This measures airflow and lung
    [Show full text]
  • Commonly Used Lipidcentric ICD-10 (ICD-9) Codes
    Commonly Used Lipidcentric ICD-10 (ICD-9) Codes *This is not an all inclusive list of ICD-10 codes R.LaForge 11/2015 E78.0 (272.0) Pure hypercholesterolemia E78.3 (272.3) Hyperchylomicronemia (Group A) (Group D) Familial hypercholesterolemia Grütz syndrome Fredrickson Type IIa Chylomicronemia (fasting) (with hyperlipoproteinemia hyperprebetalipoproteinemia) Hyperbetalipoproteinemia Fredrickson type I or V Hyperlipidemia, Group A hyperlipoproteinemia Low-density-lipoid-type [LDL] Lipemia hyperlipoproteinemia Mixed hyperglyceridemia E78.4 (272.4) Other hyperlipidemia E78.1 (272.1) Pure hyperglyceridemia Type 1 Diabetes Mellitus (DM) with (Group B) hyperlipidemia Elevated fasting triglycerides Type 1 DM w diabetic hyperlipidemia Endogenous hyperglyceridemia Familial hyperalphalipoproteinemia Fredrickson Type IV Hyperalphalipoproteinemia, familial hyperlipoproteinemia Hyperlipidemia due to type 1 DM Hyperlipidemia, Group B Hyperprebetalipoproteinemia Hypertriglyceridemia, essential E78.5 (272.5) Hyperlipidemia, unspecified Very-low-density-lipoid-type [VLDL] Complex dyslipidemia hyperlipoproteinemia Elevated fasting lipid profile Elevated lipid profile fasting Hyperlipidemia E78.2 (272.2) Mixed hyperlipidemia (Group C) Hyperlipidemia (high blood fats) Broad- or floating-betalipoproteinemia Hyperlipidemia due to steroid Combined hyperlipidemia NOS Hyperlipidemia due to type 2 diabetes Elevated cholesterol with elevated mellitus triglycerides NEC Fredrickson Type IIb or III hyperlipoproteinemia with E78.6 (272.6)
    [Show full text]
  • Lipid Profile Abnormalities Seen in T2DM Patients in Primary Healthcare in Turkey: a Cross-Sectional Study Aclan Ozder
    Ozder Lipids in Health and Disease 2014, 13:183 http://www.lipidworld.com/content/13/1/183 RESEARCH Open Access Lipid profile abnormalities seen in T2DM patients in primary healthcare in Turkey: a cross-sectional study Aclan Ozder Abstract Background: Diabetes is characterized by chronic hyperglycemia and disturbances of carbohydrate, lipid and protein metabolism. We aimed to research association between serum lipid profile and blood glucose, hypothesizing that early detection and treatment of lipid abnormalities can minimize the risk for atherogenic cardiovascular disorder and cerebrovascular accident in patients with type 2 diabetes mellitus. Methods: Fasting blood glucose (FBG), total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL), triglyceride (TG) and glycated haemoglobin (HbA1c) levels were evaluated. A hepatic ultrasound was performed for every diabetic to evaluate hepatosteatosis. The study was done from January 2014 to June 2014 among 132 patients with T2DM who were admitted to outpatient clinic of Family Medicine department in a university hospital. The patients whose taking multi-vitamin supplementation or having hepatic, renal or metabolic bone disorders (including parathyroid related problems) were excluded from the study for the reason that those conditions might affect the carbohydrate and lipid metabolism in diabetes. Test of significance was calculated by unpaired student’s t test between cases and controls. Correlation studies (Pearson’s correlation) were performed between the variables of blood glucose and serum lipid profile. Significance was set at p<0.05. Results: Results of serum lipid profile showed that the mean values for TC, TG, HDL and LDL in female patients were 227.6 ± 57.7 mg/dl, 221.6 ± 101.1 mg/dl, 31.5 ± 6.7 mg/dl and 136.5 ± 43.7 mg/dl, respectively.
    [Show full text]
  • Lipid Guidelines 2018: Updates from ACC/AHA Guidelines 2013
    Lipid Guidelines 2018: Updates from ACC/AHA Guidelines 2013 Allen Adolphe M.D., Ph.D. FACP Professor and Vice Chief General Internal Medicine, University of New Mexico Objectives and Disclosures • Disclosures: NIH GRADE Study; Pharmaceutical Trials, none active now • Objectives – Know the four categories of high CVD risk from the ACC/AHA 2013 Lipid Guidelines (ATP IV) – Know what the major philosophical change between ATP III and ATP IV – Know what the ACC Expert Consensus Decision Pathway is and what changes in the ACC/AHA guidelines are suggested ATP IV: a little more abstract ATP III ATP IV • RISK FACTOR COUNTING • THERE IS NO TARGET • TREAT TO LDL GOAL • THE OF • ADDRESS NON-HDL TARGET INTENSITY STATIN THERAPY IS THE FOCUS OF TREATMENT ATP-IV (ACC-AHA 2013 Guidelines) • How many of you have adopted the ATP IV guidelines in your lipid practice by reducing the LDL-C by >50% for those at high risk of CVD? • How many of you believe that if the LDL-C too low it will place patients at risk for adverse effects? • How many of you treat patient with Familial Hyperlipidemia? A Comparative Analysis of Current Lipid Treatment Guidelines RISK ESTIMATORS • Risk estimators are derived from large studies in the United States or Europe. All include age, sex, total cholesterol, HDL-C, and systolic blood pressure as predictors. • However, ethnicity, treatment for hypertension, diabetes, and smoking status are only included in some; thus, patient risk may vary with different estimators. Outcomes are different between risk estimators • Outcome for the FRS is the most inclusive, predicting 10-year risk of coronary heart disease, cerebrovascular events, peripheral artery disease, or heart failure.
    [Show full text]
  • Association Between Level of Hba1c and Lipid Profile in T2DM Patients Attending Diabetic OPD at BPKIHS
    Baranwal et.al. Association between level of HbA1c and lipid profile Original Article Health Renaissance 2015;13(3): 16-23 Association between level of HbA1c and lipid profile in T2DM patients attending diabetic OPD at BPKIHS JK Baranwal 1, R Maskey 2, S Majhi 3, M Lamsal 1, N Baral 1 Department of Biochemistry 1, Department of Internal Medicine 2, Department of Biochemistry B.P. Koirala Institute of Health Sciences, Xavier University 3 Abstract Hyperglycemia, dyslipidemia and coronary artery disease relate well with each other in type 2 diabetes and it has been proposed that higher prevalence of cardiovascular disease in type 2 diabetes is due to chronic uncontrolled hyperglycemia. Our study aimed to find utility of Hba1c as indicator of dyslipidemia in patients with type 2 diabetes mellitus. We enrolled 168 T2DM patients in our study and collected venous blood samples in both plain and EDTA vials after a fast of minimum 8 hours. Biochemical analysis was done in fully automated analyzer cobas c311. HbA1c was found to have significant positive correlation with total cholesterol, LDL-C, and triglyceride and significant negative correlation with HDL-C and HDL/LDL ratio. The mean value of TC, LDL-C and TG was found to be lower in patients with good glycemic control than those with poor glycemic control. But, mean value of HDL and HDL/LDL ratios were found to be higher in patients with good glycemic control than those with poor glycemic control. These differences were significant at the level of p <0.05. Our study suggests additional use of HbA1c as indicator of dyslipidemia.
    [Show full text]
  • Cholesterol and Kidney Disease What You Need to Know
    CHOLESTEROL AND KIDNEY DISEASE WHAT YOU NEED TO KNOW WHAT IS CHOLESTEROL? Ã Cholesterol is a type of fat (lipid) found in your blood and other parts of the body. Your body needs small amounts of cholesterol to work normally. Your body can make cholesterol, or get it from certain foods. Ã There are different kinds of cholesterol: Ã LDL cholesterol: Known as the “bad” cholesterol. Too much of it can cause harmful buildup and blockage in your arteries (a type a blood vessel) and causes heart and blood vessel disease. Ã HDL cholesterol: Known as “good” cholesterol. It helps prevent cholesterol from building up in your arteries. Ã Triglyceride: Another type of fat or lipid. Too much of it can also increase your risk for heart and blood vessel disease. Ã A blood test called a complete lipid profile is used to test cholesterol levels. A lipid profile measures for total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. WHAT IS CKD? Ã Chronic kidney disease (CKD) is a loss of kidney function that happens gradually, and which has been present for 3 or more months. In CKD, the kidneys become less able to perform many vital functions, including removing wastes from the body, balancing the body’s fluids, regulating blood pressure, producing red blood cells, and maintaining healthy bones. Ã Urine and blood tests can check for signs of CKD. Albumin-to-creatinine ratio (ACR) is a urine test that checks for high protein in the urine, which is a sign of kidney damage. Glomerular filtration rate (GFR) is a blood test that checks how well the kidneys are filtering.
    [Show full text]
  • Evaluation of Serum Lipid Profile in Patients with Hyperthyroidism
    Original Research Article DOI: 10.18231/2394-6377.2017.0030 Evaluation of serum lipid profile in patients with hyperthyroidism Anju Sharma1, Jaskiran Kaur2,*, Amandeep Kaur3, Neha Uppal4, Mandeep Kaur5 1,5Assistant Professor, 2Professor, 3,4Associate Professor, Dept. of Biochemistry, Sri Guru Ram Institute of Medical Sciences & Research *Corresponding Author: Email: [email protected] Abstract Introduction: Thyroid dysfunctions are known to influence lipid metabolism significantly, affects lipoprotein metabolism. Hyperthyroidism is associated with lipid alterations mainly concerning total and LDL cholesterol. Materials and Method: It was a case control study. The cases and controls were screened for serum thyroid profile and complete lipid profile, the values were compared with that of normal healthy subjects. The cases were divided into two groups after studying the thyroid profile i.e. subclinical hyperthyroidism (characterized by low serum TSH with normal T4) and overt hyperthyroidism (characterized by low TSH and with elevated FT4). Results: The descriptive data was given as mean ± standard deviation. The statistical analysis was done by ANOVA and student t test. The mean difference was significant at the 0.05 level and statistically insignificant when the p value obtained was greater than 0.05. The mean serum total cholesterol & LDL levels were decreased in patients of overt hyperthyroidism as compared to controls and the difference between the levels was statistically insignificant. But the mean serum TG remain unchanged in patients and the difference was statistically insignificant. In the cases of subclinical hyperthyroidism the mean serum levels of total cholesterol, LDL & TG were decreased in patients as compared to controls & the difference was statistically insignificant.
    [Show full text]